Advertisement

Topics

Latest "Pharmaceuticals" News Stories

05:02 EDT 18th July 2018 | BioPortfolio

Here are the most relevant search results for "Pharmaceuticals" found in our extensive news archives from over 250 global news sources.

More Information about Pharmaceuticals on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Pharmaceuticals for you to read. Along with our medical data and news we also list Pharmaceuticals Clinical Trials, which are updated daily. BioPortfolio also has a large database of Pharmaceuticals Companies for you to search.

Showing "Pharmaceuticals" News Articles 1–25 of 7,600+

Relevant

Critical Contrast: Ironwood Pharmaceuticals

Ironwood Pharmaceuticals and Infinity Pharmaceuticals are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership and earnings. Infinity Pharmaceuticals has lower revenue, but higher earnings than Ironwood Pharmaceuticals.


Probably Relevant

Telix Pharmaceuticals Limited: Telix Pharmaceuticals, INSERM and ARRONAX Enter into Translational Research Partnership

MELBOURNE, Australia and NANTES, France, April 16, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:TLX) ("Telix", the "Company"), a clinical-stage biopharmaceutical company focused on ...

Newly Merged Amneal Pharmaceuticals to Push into the Biosimilar Space

Earlier this week Amneal Pharmaceuticals and Impax Laboratories completed their business merger, forming the new Amneal Pharmaceuticals. The combined companies are now the fifth largest generics business in the United States.


Emerald Health Pharmaceuticals Inc.: Emerald Health Pharmaceuticals to Present at Cannabis Invest UK Conference

SAN DIEGO, CA / ACCESSWIRE / April 19, 2018 / Emerald Health Pharmaceuticals Inc. (EHP), which is developing medicines based on cannabinoid science, announced today that Dr. Jim DeMesa, CEO, will p...

Cantex Pharmaceuticals, Inc. Announces FDA Orphan Drug Designation Has Been Granted to CX-01 for Treatment of Acute Myeloid Leukemia

WESTON, Fla., January 3, 2018 -- Cantex Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing proprietary pharmaceuticals that improve the treatment of cancers and other life-threatening disorders, today announced that the...

20182023 UK BFS BlowFillSeal Products Market Report Status and Outlook [Report Updated: 15062018] Prices from USD $3360

In 2017, the BFS BlowFillSeal Products market size was xx million USD in UK, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023.In UK market, the top players include Unither Pharmaceuticals Nephron Pharmaceuticals Takeda Pharmaceuticals Recipharm TRC SIFI Catalent Horizon Pharmaceuticals Unicep Packaging Amanta Healthcare CR DoubleCrane...

Telix Pharmaceuticals Limited: Telix Pharmaceuticals and Radboud University Medical Centre Conclude Clinical Collaboration Agreement

MELBOURNE, Australia and NIJMEGAN, The Netherlands, March 15, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) ("Telix", the "Company"), a clinical-stage biopharmaceutical company ...

Veloxis Pharmaceuticals A/S: Veloxis Pharmaceuticals Releases Annual Report for 2017

Company Release no. 2/2018To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 27 February 2018 Veloxis Pharmaceuticals Releases Annual Report for 2017 Veloxis Pharmaceuticals A/S (OMX: VELO) today publi...

Emerald Health Pharmaceuticals Inc.: Emerald Health Pharmaceuticals to Participate in Neuroscience Panel and Present at Sachs BioCapital USA Forum

SAN DIEGO, CA / ACCESSWIRE / March 13, 2018 / Emerald Health Pharmaceuticals, Inc. (EHP), which is developing medicines based on cannabinoid science, announced today that Dr. Jim DeMesa, CEO, will ...

Immune Pharmaceuticals Inc.: Immune Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 12, 2018

ENGLEWOOD CLIFFS, NJ / ACCESSWIRE / February 6, 2018 / Immune Pharmaceuticals Inc. (NASDAQ: IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic a...

COSMO Pharmaceuticals N.V.: Cosmo Pharmaceuticals Antrag auf Kündigung der; Lizenzvereinbarung mit Valeant vom Schiedsgericht abgelehnt

Cosmo Pharmaceuticals Antrag auf Kündigung derLizenzvereinbarung mit Valeant vom Schiedsgericht abgelehnt Dublin - 12. April 2018 - Cosmo Pharmaceuticals N.V. (SIX: COPN) informierte, das ICC-Schi...

20182023 Philippines BFS BlowFillSeal Products Market Report Status and Outlook [Report Updated: 15062018] Prices from USD $3360

In 2017, the BFS BlowFillSeal Products market size was xx million USD in Philippines, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023.In Philippines market, the top players include Unither Pharmaceuticals Nephron Pharmaceuticals Takeda Pharmaceuticals Recipharm TRC SIFI Catalent Horizon Pharmaceuticals Unicep Packaging Amanta Healthcare...

20182023 Malaysia BFS BlowFillSeal Products Market Report Status and Outlook [Report Updated: 15062018] Prices from USD $3360

In 2017, the BFS BlowFillSeal Products market size was xx million USD in Malaysia, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023.In Malaysia market, the top players include Unither Pharmaceuticals Nephron Pharmaceuticals Takeda Pharmaceuticals Recipharm TRC SIFI Catalent Horizon Pharmaceuticals Unicep Packaging Amanta Healthcare CR...

20182023 India BFS BlowFillSeal Products Market Report Status and Outlook [Report Updated: 15062018] Prices from USD $3360

In 2017, the BFS BlowFillSeal Products market size was xx million USD in India, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023.In India market, the top players include Unither Pharmaceuticals Nephron Pharmaceuticals Takeda Pharmaceuticals Recipharm TRC SIFI Catalent Horizon Pharmaceuticals Unicep Packaging Amanta Healthcare CR Doubl...

Surface Pharmaceuticals secures $20m funding from Flying L Partners

Surface Pharmaceuticals, an affiliated company of Imprimis Pharmaceuticals, has entered into a definitive stock purchase agreement with an affiliate of Flying L Partners to raise proceeds of about $20m in a private placement of its Series A preferred stock.

BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at the JMP Securities Life Sciences Conference

RESEARCH TRIANGLE PARK, N.C. and EXTON, Pa., June 13, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (“BioCryst”) (NASDAQ:BCRX), and Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ:IDRA), today announced that they will be presenting at the JMP Securities Life Sciences Conference on Thursday, June 21, 2018 at 10:00 A.M. E.T.  ...

BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at Two Upcoming Healthcare Investor Conferences

RESEARCH TRIANGLE PARK, N.C. and EXTON, Pa., Feb. 19, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), and Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), today announced they will be presenting at two upcoming healthcare-focused investor conferences.

Elite Pharmaceuticals Announces Strategic Marketing Alliance with Glenmark Pharmaceuticals, Inc., USA

NORTHVALE, N.J., May 29, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc (OTCBB:ELTP) announced today the signing of a license, manufacturing, and supply agreement with Glenmark Pharmaceuticals, Inc., USA to market two Elite generic products in the United States with the option to add products in the future.  Through the agreement, Glenmark will sell and distribute the products and Elite...

Idera Pharmaceuticals Announces Termination of Merger Agreement with BioCryst Pharmaceuticals

EXTON, Pa., July 10, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) announced today that the Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) entered into by and among Idera and BioCryst on January 22, 2018, has been terminated.  The Merger Agreement was terminated following the July 10, 2018 special meeting of BioCryst stockholders at which BioC...

Contrasting Adamis Pharmaceuticals

Adamis Pharmaceuticals and Impax Laboratories are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, analyst recommendations, risk and dividends. 16.5% of Adamis Pharmaceuticals shares are held by institutional investors.

BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference

RESEARCH TRIANGLE PARK, N.C. and EXTON, Pa., March 22, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (“BioCryst”) (NASDAQ:BCRX), and Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ:IDRA), today announced they will be presenting at the 17th Annual Needham Healthcare Conference on Tuesday, March 27, 2018 at 12:15 P.M. E.T.  The conference is being held at the Westin New York Gr...

BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference

RESEARCH TRIANGLE PARK, N.C. and EXTON, Pa., May 24, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (“BioCryst”) (NASDAQ:BCRX), and Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ:IDRA), today announced that they will be presenting at the Jefferies 2018 Global Healthcare Conference on Thursday, June 7, 2018 at 8:30 A.M. E.T.  ...

Sedor Pharmaceuticals and Los Altos Pharmaceuticals sign license agreement for People’s Republic of China

PAOLI, Pa. and LOS ALTOS HILLS, Calif., May 30, 2018 (GLOBE NEWSWIRE) -- Sedor Pharmaceuticals, LLC (Sedor) and Los Altos Pharmaceuticals, Inc. (Los Altos) announce that Sedor has granted Los Altos an exclusive license for Captisol-enabled™ (CE) Meloxicam for the People’s Republic of China (PRC). Los Altos, located in Los Altos Hills, CA, has received exclusive development, manufacturing an...

RA Capital Management Opposes BioCryst Pharmaceuticals' Proposed Merger with Idera Pharmaceuticals

BioCryst Pharmaceuticals, Inc. 4505 Emperor Blvd., Suite 200 Durham, North Carolina27703 Attn: Board of Directors Dear Board Members: Our firm, RA Capital Management ("RA Read more...

COSMO Pharmaceuticals N.V.: Cosmo Pharmaceuticals' Aktion ä re stimmen; an der Generalversammlung allen Traktanden zu

Cosmo Pharmaceuticals' Aktionäre stimmenan der Generalversammlung allen Traktanden zu Amsterdam - 30. Mai 2018 - Die Aktionäre von Cosmo Pharmaceuticals N.V. (SIX: COPN) haben an der Generalversam...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks